Latest news for Terna Energy (OTC:TREAF) Stock

Terna Energy SA is a Greece based company mainly engaged in the energy and construction sector. It operates through the following segments: The Construction segment refers to the development of wind farms and other units for electricity production from renewable energy sources; The Electricity from Renewable Sources of Energy segment mainly concerns the production of electricity through wind energy; The Concessions Segment concerns the construction and operation of infrastructure and public sector projects in exchange for the long-term operation of the above projects through the provision of services to the public. The majority is from the Electricity from Renewable Sources of Energy segment. Geographically, the key revenue is from Greece.

Terna Energy SA

On November 14, 2024, Zhejiang ZEEKR Intelligent Technology Co., Ltd ("Zhejiang ZEEKR"), ZEEKR's indirect wholly-owned PRC subsidiary principally engaged in the sale of vehicles, entered into an equity transfer agreement (the "LYNK &amp; CO Equity Transfer Agreement") with Geely Holding, VCI and LYNK &amp; CO, pursuant to which Zhejiang ZEEKR will acquire a 20% interest in LYNK &amp; CO from Geely Holding and a 30% interest in LYNK &amp; CO from VCI (collectively, the "Equity Transfer") at a purchase price of RMB3.6 billion and RMB5.4 billion, respectively

News

Reported Earlier, Zhejiang ZEEKR To Acquire 50% Stake In LYNK & CO From Geely Holding And VCI For RMB9B

Shares of DLocal Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLO#NASDAQ">DLO</a>) rose sharply in today's pre-market trading after the company reported better-than-expected <a href="https://www.benzinga.com/quote/DLO/earnings">third-quarter revenue results</a>.
DLocal reported quarterly earnings of 9 cents per share which missed the analyst consensus estimate of 11 cents per share. The company reported quarterly sales of $185.774 million which beat the analyst consensus estimate of $181.463 million.
DLocal shares jumped 18.3% to $10.70 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Elevai Labs Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELAB#NASDAQ">ELAB</a>) gained 91.1% to $0.0472 in pre-market trading after surging 32% on Wednesday.</li>
<li>SRIVARU Holding Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SVMH#NASDAQ">SVMH</a>) rose 40% to $0.0339 in pre-market trading.</li>
<li>XTI Aerospace, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XTIA#NASDAQ">XTIA</a>) gained 35.7% to $0.0777 in pre-market trading after gaining 18% on Wednesday.</li>
<li>Nuburu, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BURU#NASDAQ">BURU</a>) gained 28.7% to $0.5335 in pre-market trading.</li>
<li>Zoomcar Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZCAR#NASDAQ">ZCAR</a>) gained 26.9% to $8.25 in pre-market trading after the company reported second-quarter results.</li>
<li>Quantum Computing Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QUBT#NASDAQ">QUBT</a>) climbed 25.8% to $3.34 in pre-market trading after jumping more than 92% on Wednesday.</li>
<li>Zeta Global Holdings Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZETA#NYSE">ZETA</a>) gained 20.5% to $21.40 in pre-market trading. Zeta Global increased its share repurchase program with $100 million buyback authorization through 2026.</li>
<li>1847 Holdings LLC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EFSH#NYSE">EFSH</a>) gained 17.7% to $0.5301 in pre-market trading after dipping 58% on Wednesday.</li>
<li>D-Wave Quantum Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QBTS#NYSE">QBTS</a>) gained 14.6% to $2.04 in pre-market trading.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Calidi Biotherapeutics, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLDI#NYSE">CLDI</a>) shares tumbled 27% to $2.47 in pre-market trading after the company announced a proposed public offering.</li>
<li>Digital Brands Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBGI#NASDAQ">DBGI</a>) shares fell 26.5% to $0.1329 in pre-market trading after jumping over 40% on Wednesday.</li>
<li>Harrow, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HROW#NASDAQ">HROW</a>) declined 25.8% to $38.45 in pre-market trading after the company reported worse-than-expected third-quarter sales results.</li>
<li>Ibotta, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBTA#NYSE">IBTA</a>) shares fell 22.9% to $57.75 in pre-market trading after the company reported quarterly results.</li>
<li>Cyclacel Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>) fell 18.7% to $0.3658 in pre-market trading after gaining around 10% on Wednesday.</li>
<li>Bluejay Diagnostics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BJDX#NASDAQ">BJDX</a>) dipped 18.3% to $0.0850 in pre-market trading after the company reported a 1-for-50 reverse stock split.</li>
<li>Matinas BioPharma Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTNB#NYSE">MTNB</a>) shares dipped 15.9% to $0.5969 in pre-market trading after falling around 5% on Wednesday.</li>
<li>ESS Tech, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GWH#NYSE">GWH</a>) fell 13.8% to $7.68 in pre-market trading following third-quarter results.</li>
<li>Taysha Gene Therapies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSHA#NASDAQ">TSHA</a>) fell 10.8% to $1.9700 in pre-market trading following third-quarter results.</li>
<li>Super Micro Computer, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) fell 10.1% to $18.27 in today's pre-market trading. Super Micro Computer shares fell 6% on Wednesday after the company announced it was unable to file its quarterly report for the period ending Sept. 30 in a timely manner.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/11/41962884/us-stocks-settle-mixed-following-inflation-data-investor-sentiment-improves-but-fear-index-remains-in-greed-zone">US Stocks Settle Mixed Following Inflation Data: Investor Sentiment Improves, But Fear Index Remains In &#8216;Greed&#8217; Zone</a></li>
</ul>

Pre-Market Outlook

Markets

Movers

Trading Ideas

BJDX

BURU

CLDI

CYCC

DBGI

EFSH

ELAB

HROW

IBTA

MTNB

QBTS

QUBT

SMCI

SVMH

TSHA

XTIA

ZCAR

ZETA

Why DLocal Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket

Xunlei (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XNET#NASDAQ">XNET</a>) reported quarterly earnings of $0.08 per share. This is a 3.57 percent decrease over earnings of $0.08 per share from the same period last year. The company reported $79.84 million in sales this quarter. This is a 4.90 percent decrease over sales of $83.95 million the same period last year.

Earnings

XNET

Xunlei Q3 2024 Adj EPADS $0.0805 Down From $0.0835 YoY, Sales $79.84M Down From $83.95M YoY

HC Wainwright &amp; Co. analyst Edward White reiterates Aura Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AURA#NASDAQ">AURA</a>) with a Buy and maintains $22 price target.

Price Target

Reiteration

Analyst Ratings

AURA

HC Wainwright & Co. Reiterates Buy on Aura Biosciences, Maintains $22 Price Target

HC Wainwright &amp; Co. analyst Douglas Tsao maintains Viridian Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRDN#NASDAQ">VRDN</a>) with a Buy and raises the price target from $27 to $34.

VRDN

HC Wainwright & Co. Maintains Buy on Viridian Therapeutics, Raises Price Target to $34

Macro Economic Events

Econ #s

Economics

Eurozone Industrial Production (MoM) For September -2.0% Vs. -1.3% Est.; 1.5% (Revised) Prior

Eurozone Gross Domestic Product (QoQ) Preliminary For Q3 0.4% Vs. 0.4% Est.; 0.4% Prior

HC Wainwright &amp; Co. analyst Douglas Tsao reiterates Biohaven (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BHVN#NYSE">BHVN</a>) with a Buy and maintains $59 price target.

BHVN

HC Wainwright & Co. Reiterates Buy on Biohaven, Maintains $59 Price Target

Rolling out globally across the US, Germany, Italy and Spain, the new experience gives customers the ability to set up a pool in the PayPal app or online, invite friends and family to contribute, track group contributions and transfer funds to their PayPal balance to spend or withdraw.

Tech

General

PYPL

PayPal Announced A New Experience That Makes It Easy For Customers To Pool Money With Friends And Family For Group Gifts, Travel, Special Events, Or Other Shared Expenses

Eurozone Gross Domestic Product (YoY) Preliminary For Q3 0.9% Vs. 0.9% Est.; 0.9% Prior

The Company announced today that its board of directors has authorized a share repurchase program under which the Company may repurchase up to US$200 million of its publicly traded securities for the next 24 months.

Buybacks

BILI

Bilibili Board Approved A Share Buyback Program Of Up To $200M For Next 24 Months

HC Wainwright &amp; Co. analyst Heiko Ihle maintains Avino Silver &amp; Gold Mines (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ASM#AMEX">ASM</a>) with a Buy and raises the price target from $1.5 to $1.8.

HC Wainwright & Co. Maintains Buy on Avino Silver & Gold Mines, Raises Price Target to $1.8

Bilibili Q3 Adj EPS $0.08 Misses $0.10 Estimate, Sales $1.04B Beat $1.01B Estimate

Stifel analyst Stephen Willey maintains X4 Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XFOR#NASDAQ">XFOR</a>) with a Buy and lowers the price target from $5 to $4.

XFOR

Stifel Maintains Buy on X4 Pharmaceuticals, Lowers Price Target to $4

HC Wainwright &amp; Co. analyst Patrick Trucchio reiterates Voyager Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VYGR#NASDAQ">VYGR</a>) with a Buy and maintains $30 price target.

VYGR

HC Wainwright & Co. Reiterates Buy on Voyager Therapeutics, Maintains $30 Price Target

Piper Sandler analyst Michael Lavery upgrades Campbell Soup (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPB#NASDAQ">CPB</a>) from Neutral to Overweight and raises the price target from $47 to $56.

Upgrades

Piper Sandler Upgrades Campbell Soup to Overweight, Raises Price Target to $56

HC Wainwright &amp; Co. analyst Andres Maldonado reiterates Mural Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MURA#NASDAQ">MURA</a>) with a Buy and maintains $18 price target.

MURA

HC Wainwright & Co. Reiterates Buy on Mural Oncology, Maintains $18 Price Target

Mizuho analyst Haendel St. Juste maintains Agree Realty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ADC#NYSE">ADC</a>) with a Neutral and raises the price target from $75 to $80.

Mizuho Maintains Neutral on Agree Realty, Raises Price Target to $80

HC Wainwright &amp; Co. analyst Yi Chen reiterates Clearside Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLSD#NASDAQ">CLSD</a>) with a Buy and maintains $6 price target.

CLSD

HC Wainwright & Co. Reiterates Buy on Clearside Biomedical, Maintains $6 Price Target

Mizuho analyst Vikram Malhorta maintains Essential Props Realty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EPRT#NYSE">EPRT</a>) with a Outperform and raises the price target from $31 to $35.

EPRT

Mizuho Maintains Outperform on Essential Props Realty, Raises Price Target to $35

Terna Energy

Comments

Terna Energy

News

Latest news for Terna Energy (OTC:TREAF) Stock

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga